tocacco plant Native American Tobaccoo flower, leaves, and buds

tocacco Tobacco is an annual or bi-annual growing 1-3 meters tall with large sticky leaves that contain nicotine. Native to the Americas, tobacco has a long history of use as a shamanic inebriant and stimulant. It is extremely popular and well-known for its addictive potential.

tocacco nicotina Nicotiana tabacum

tocacco Nicotiana rustica leaves. Nicotiana rustica leaves have a nicotine content as high as 9%, whereas Nicotiana tabacum (common tobacco) leaves contain about 1 to 3%

tocacco cigar A cigar is a tightly rolled bundle of dried and fermented tobacco which is ignited so that its smoke may be drawn into the mouth. Cigar tobacco is grown in significant quantities in Brazil, Cameroon, Cuba, Dominican Republic, Honduras, Indonesia, Mexico, Nicaragua, Sumatra, Philippines, and the Eastern United States.

tocacco Tobacco is an agricultural product processed from the fresh leaves of plants in the genus Nicotiana. It can be consumed, used as an organic pesticide, and in the form of nicotine tartrate it is used in some medicines. In consumption it may be in the form of cigarettes smoking, snuffing, chewing, dipping tobacco, or snus.

tocacco Cigarettes are smoking products consumed by people and made out of cut tobacco leaves. Cigars are typically composed completely of whole-leaf tobacco. A cigarette has smaller size, composed of processed leaf, and white paper wrapping. The term cigarette refers to a tobacco cigarette too but it can apply to similar devices containing other herbs, such as cannabis.
Tobacco-Facts ads

Drug may prevent lung cancer, US study finds

WASHINGTON, - A drug approved to treat a range of conditions may also work to prevent lung cancer in people who have given up smoking, U.S. researchers reported on Tuesday.

The drug, called iloprost, is approved in inhaled forms to treat pulmonary hypertension, when blood pools near the lungs, a connective tissue disease called scleroderma and a nerve condition called Raynaud’s phenomenon.

Dr. Robert Keith of the Denver Veterans Affairs Medical Center and colleagues tested an oral version to see if it might prevent lung cancer in smokers and former smokers.

“Oral iloprost showed promise for preventing lung cancer in former, but not current, smokers in a phase II clinical trial,” they wrote in a summary presented to a meeting of the American Thoracic Society in New Orleans.

Iloprost is a version of prostacyclin, a drug in the prostaglandin class that prevents lung cancer in mice.

Keith, who has been testing several drugs to prevent lung cancer, looked at biopsies taken from the lungs of 125 current and former smokers.

They treated half with placebo and half with iloprost, and then performed bronchoscopy examinations to assess precancerous changes in the lungs.

Six months later, “former smokers showed significant improvements on all measures, indicating that treatment with iloprost may reduce the risk of developing lung cancer among former smokers,” the researchers said.

“Interestingly, current smokers did not show any significant improvements,” they added.

“Oral iloprost significantly improves endobronchial dysplasia in former smokers and deserves further study to determine if it can prevent the development of lung cancer.”

ITALIAN RESEARCH

Swiss drug maker Actelion (ATLN.VX) markets inhaled iloprost under the brand name Ventavis.

It is also sold in an intravenous form under the trade name Ilomedin by Schering, acquired by Merck (MRK.N).

In April, researchers said a natural supplement derived from food, called myo-inositol, seems to stop the precancerous changes that lead to lung cancer.

Cigarette smoke causes 90 percent of all cases of lung cancer, which kills 1.2 million people a year globally. But only about 10 percent of smokers ever develop lung cancer, although they often die of other causes like heart disease, stroke or emphysema.

Separately, Italian researchers reported that advanced lung cancer patients given the targeted therapy drug Tarceva as so-called maintenance treatment — after they finished a course of standard chemotherapy — lived a little bit longer.

Federico Cappuzzo from Ospedale Civile di Livorno in Italy and colleagues did a phase 3 trial in 889 patients who had already had chemotherapy and whose tumors had not come back.

They received either Tarceva, a drug sold by Roche (ROG.VX) and OSI Pharmaceuticals (OSIP.O) and known generically as erlotinib, or a placebo until they got worse or died.

The patients who got Tarceva lived a little longer without their tumors growing — 12 weeks versus 11 weeks on average and they lived a month longer on average - 12 months versus 11 months.

This was seen even among patients who did not have the EGFR genetic mutation that Tarceva targets, they reported in Lancet Oncology.

Fewer than half of all lung cancer patients who do well after a first course of chemotherapy get more treatment, but the Italian group said their study shows this is worth doing.

By Maggie Fox, Reuters

Share and Enjoy:
  • Digg
  • del.icio.us
  • Facebook
  • Technorati
  • StumbleUpon
  • Google Bookmarks
  • MySpace
  • MyShare
  • RSS
  • Twitter
  • Simpy
  • Sphinn
  • Yahoo! Buzz
  • Blogosphere News
  • Mixx
  • Reddit
  • Propeller
  • MisterWong
  • LinkedIn
Tobacco-Facts ads
discount cigarettes

Leave a Reply

 

 

 

You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

*
To prove you're a person (not a spam script), type the security word shown in the picture. Click on the picture to hear an audio file of the word.
Click to hear an audio file of the anti-spam word